A cost evaluation of treatment alternatives in mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Turkey (original) (raw)
A cost evaluation of treatment alternatives for mild-to-moderate bleeding episodes in patients with haemophilia and inhibitors in Brazil
M. Ozelo
Haemophilia, 2007
View PDFchevron_right
A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors
Anne Møller Danø
Haemophilia, 2009
View PDFchevron_right
aPCC vs. rFVIIa for the treatment of bleeding in patients with acquired haemophilia – a cost‐effectiveness model
châu bùi
Vox Sanguinis, 2018
View PDFchevron_right
A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high-titre inhibitors
Rhonda Bohn
Haemophilia, 2005
View PDFchevron_right
Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic
U. Hedner
Haemophilia, 2009
View PDFchevron_right
Cost Components of Treatment Protocols of Haemophilia Patients with Inhibitors using Bypassing Agents in Iran
Mina Golestani
Iranian Journal of Pharmaceutical Sciences, 2016
View PDFchevron_right
A Rebuttal to the Commentary of J. W. Hay and Z.-Y. Zhou. Haemophilia 2009; DOI:10.1111/j.1365-2516.2009.02117.x: “Commentary on Knight et al.: A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding ep
Chris Knight
Haemophilia, 2010
View PDFchevron_right
Pharmacoeconomic analysis of recombinant factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in hemophilia patients with inhibitors
Jennifer Stephens
Current Medical Research and Opinion, 2005
View PDFchevron_right
Pharmacoeconomic studies of bypassing agents in mild-to-moderate bleeding episodes in patients with hemophilia and inhibitors: a critical appraisal
Erich de Paula
View PDFchevron_right
Bypassing Agents for Bleeding Reduction in Treatment of Bleeding Episodes in Patients With Haemophilia and Inhibitors
Jamshid Salamzadeh
Iranian Red Crescent Medical Journal, 2014
View PDFchevron_right
Comparison of Bypassing Agents in Bleeding Reduction in Treatment of Bleeding Episodes in Patients with Haemophilia and Inhibitors (Review Article)
Ali Imani
2014
View PDFchevron_right
Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group
Alessandro Gringeri
Blood, 2003
View PDFchevron_right
The Impact of Factor VIII Inhibitors on Factor Consumption in Haemophilia A: A Case-Control Study in South of Iran
Kimia Pourmohammadi
View PDFchevron_right
Modeling costs and outcomes associated with a treatment algorithm for problem bleeding episodes in patients with severe hemophilia a and high-titer inhibitors
Alessandro Gringeri
American health & drug benefits, 2011
View PDFchevron_right
The value of early treatment in patients with haemophilia and inhibitors
B. Antmen
Haemophilia, 2010
View PDFchevron_right
Real-World Rates of Bleeding, Factor VIII Use, and Quality of Life in Individuals with Severe Haemophilia A Receiving Prophylaxis in a Prospective, Noninterventional Study
divya reddy
Journal of Clinical Medicine, 2021
View PDFchevron_right
The socio-economic burden of patients affected by Hemophilia with inhibitors
Giacomo Crotti
European Journal of Haematology, 2018
View PDFchevron_right
Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres
G. Auerswald, Carmen Altisent
Haemophilia, 2007
View PDFchevron_right
Systematic review of efficacy of rFVIIa and aPCC treatment for hemophilia patients with inhibitors
Chris Knight
Advances in Therapy, 2009
View PDFchevron_right
Cost of care of haemophilia with inhibitors
Anna Coppola
Haemophilia, 2010
View PDFchevron_right
Inhibitor Screening for Patients With Hemophilia In Turkey
Sabri KEMAHLI
View PDFchevron_right
Long-Term Outcomes of Previously Treated Adult and Adolescent Patients with Severe Hemophilia A Receiving Prophylaxis with Extended Half-Life FVIII Treatments: An Economic Analysis from a United Kingdom Perspective
XIN YI LEE
ClinicoEconomics and Outcomes Research, 2021
View PDFchevron_right
Cost-of-illness study of severe haemophilia A and B in five French haemophilia treatment centres
Marie-christine Woronoff-lemsi
Pharmacy World & Science, 2007
View PDFchevron_right
Single-dose (270 μg kg −1 ) recombinant activated factor VII for the treatment and prevention of bleeds in haemophilia A patients with inhibitors: experience from seven European haemophilia centres
Andrzej Mital
Haemophilia, 2009
View PDFchevron_right
Economic Burden of High-Responding Inhibitors in Patients with Hemophilia A in Taiwan
Thau-Ming Cham
Yonsei Medical Journal, 2013
View PDFchevron_right
Impact of pharmacokinetics to reduce bleeding in a cohort of patients with severe hemophilia A in a personalized comprehensive management program
Carol Agudelo
View PDFchevron_right
The need for speed in the management of haemophilia patients with inhibitors
Ivo V Elezovic
Haemophilia, 2011
View PDFchevron_right
Haemophilia A: Pharmacoeconomic Review of Prophylaxis Treatment versus On-Demand
Walter Ricciardi
The Scientific World Journal, 2015
View PDFchevron_right
High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis
Andrea Messori
PubMed, 2018
View PDFchevron_right
A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors
Roseline d'Oiron
Haemophilia, 2007
View PDFchevron_right
Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry
Craig Kessler
Haemophilia, 2005
View PDFchevron_right
Long-term safety and efficacy of recombinant activated factor VII (NovoSeven) in haemophilia patients with inhibitors: interim post marketing study analysis of 5 patient exposure years
Masashi Taki
Japanese Journal of Thrombosis and Hemostasis, 2006
View PDFchevron_right
The relevance of the bleeding severity in the treatment of acquired haemophilia - an update of a single-centre experience with 67 patients
N. Vidovic
Haemophilia, 2008
View PDFchevron_right
Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™) and Activated Prothrombin Complex Concentrates (FEIBA™) to Treat Hemophilia A Patients with Inhibitors in Iran
Jamshid Salamzadeh
Iranian journal of pharmaceutical research : IJPR, 2016
View PDFchevron_right
Clinicopathological parameters influencing inhibitor development in patients with hemophilia A receiving on-demand therapy
Namrata Punit Awasthi
Therapeutic Advances in Hematology, 2018
View PDFchevron_right